Spanish Stocks: Vocento, Indra Sistemas, La Seda de Barcelona Are Active

Spain’s IBEX 35 Index advanced after two days of losses, gaining 52.6, or 0.5 percent, to 10,202.1 as of 11:54 a.m. in Madrid. The measure has lost 2.2 percent this week.

The following were among the most active stocks in the Spanish market. Symbols are in parentheses after company names.

Banco Bilbao Vizcaya Argentaria SA (BBVA SM) rose 2.6 percent to 8.30 euros, snapping two days of losses. Spain’s second-biggest bank was raised to “neutral” from “sell” at UBS AG.

Banco Popular Espanol SA (POP SM) increased 3.6 percent to 4.34 euros, breaking five days of losses. Spanish banks reduced in October their European Central Bank borrowings to 67.9 billion euros from 97.7 billion euros in September, the Bank of Spain said today.

Indra Sistemas SA (IDR SM) dropped for a second day, losing 3.3 percent to 13.30 euros. Spain’s largest computer-services company said nine-month profit dropped 5 percent to 143.4 million euros ($195.5 million) as sales in Spain decreased. The company forecast a 2 percent increase in full-year sales, at the low end of a range of 2 percent to 4 percent that it set in January.

La Seda de Barcelona SA (SED SM) climbed 1.5 percent to 7 euro cents, the first gain in three days. Europe’s largest maker of polyethylene terephthalate, a type of polyester, said its nine-month net loss narrowed to 29.5 million euros from a loss of 382.4 million euros a year earlier.

Vocento SA (VOC SM) fell for a fifth day, losing 2.4 percent to 3.52 euros. Spain’s largest newspaper publisher posted a nine-month loss of 12.3 million euros, compared with a profit of 47.2 million euros a year earlier. Sales fell 4.1 percent to 531 million euros, it said.

Zeltia SA (ZEL SM) slipped for a third day, losing 2.3 percent to 2.96 euros. Centocor Ortho Biotech Products LP, the Johnson & Johnson unit that owns the marketing rights for Yondelis outside Europe and Japan, withdrew a request for approval to sell the drug in Australia and plans to present more data to regulators in that country, according to a regulatory filing from Zeltia SA, the developer of Yondelis. Centocor has won approval to sell Yondelis as a treatment for ovarian cancer in Colombia, Zeltia said.

To contact the reporter on this story: Paul Tobin in Madrid at ptobin@bloomberg.net; Manuel Baigorri in Madrid at mbaigorri@bloomberg.net.

To contact the editor responsible for this story: David Merritt at dmerritt1@bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.